Achieve Life Sciences (ACHV) Cash from Investing Activities (2010 - 2026)
Achieve Life Sciences' (ACHV) quarterly Cash from Investing Activities came in at $14.3 million in Q1 2026, up 25.75% YoY from $11.4 million in Q1 2025, and up 1913.54% on a QoQ basis from $709000.0 in Q4 2025.
Powered by 
Analysis
Achieve Life Sciences (ACHV) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Achieve Life Sciences (ACHV) has 15 years of Cash from Investing Activities data on file, last reported at $14.3 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 25.75% year-over-year to $14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.0 million (down 75.14% YoY) and the FY2025 annual result came in at $6.1 million, up 128.32% from the prior year.
- Cash from Investing Activities advanced to $14.3 million in Q1 2026, from $709000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $14.3 million in Q1 2026 to a low of -$12.7 million in Q3 2025.
- A 4-year average of $5.7 million and a median of $9.0 million in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities jumped 195383.33% — and 2025, when it sank 195.35%.
- Tracing ACHV's Cash from Investing Activities over 4 years: stood at -$6000.0 in 2023, then jumped by 195383.33% to $11.7 million in 2024, then sank by 93.95% to $709000.0 in 2025, then soared by 1913.54% to $14.3 million in 2026.
- The last three Cash from Investing Activities figures came in at $14.3 million (Q1 2026), $709000.0 (Q4 2025), and -$12.7 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Achieve Life Sciences | 369.90 Mn | 369.90 Mn | - | -137.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -137.80 Mn |
| Mar 31, 2026 | 14.28 Mn |
| Dec 31, 2025 | 709,000.00 |
| Sep 30, 2025 | -12.65 Mn |
| Jun 30, 2025 | 6.70 Mn |
| Mar 31, 2025 | 11.35 Mn |
| Dec 31, 2024 | 11.72 Mn |
| Sep 30, 2024 | 13.27 Mn |
| Dec 31, 2023 | -6,000.00 |
| Sep 30, 2020 | -3,000.00 |
| Jun 30, 2020 | -12,000.00 |
| Mar 31, 2020 | -2,000.00 |
| Dec 31, 2019 | -1,000.00 |
| Jun 30, 2019 | 2.35 Mn |
| Mar 31, 2019 | 2.69 Mn |
| Dec 31, 2018 | -3.71 Mn |
| Sep 30, 2018 | -1.39 Mn |
| Jun 30, 2018 | -36,000.00 |
| Mar 31, 2018 | 10,000.00 |
| Dec 31, 2017 | 272,000.00 |